In situ vaccination with CXCL9/10-DC provided broad antitumor efficacy in multiple murine models of lung cancer and augmented the effectiveness of anti-PD-1 therapy in murine models of LKB1-deficient NSCLC. The gene discussed is CXCL9; the disease is lung carcinoma.